<DOC>
	<DOCNO>NCT02777073</DOCNO>
	<brief_summary>1 . To compare level ketone body ( beta-hydroxybutyrate acetoacetate ) plasma urine follow single dose treatment either liraglutide 1.8mg , dapagliflozin 10mg placebo insulinopenic state . 2 . To compare plasma level free fatty acid , glucagon , hs-CRP , Il-6 IL-1 administration liraglutide/Dapagliflozin/placebo .</brief_summary>
	<brief_title>Effects Single Doses Liraglutide Dapagliflozin Hyperglycemia Ketogenesis Type 1 Diabetes</brief_title>
	<detailed_description>Diabetic ketoacidosis important cause mortality morbidity type 1 patient . The decreased ratio insulin glucagon insulin deficient subject promote ketogenesis . In patient type 1 diabetes , suppressive effect hyperglycemia paracrine inhibitory effect insulin GABA β cell α cell absent . Thus , plasma glucagon concentration elevate combination insulin deficiency , lead lipolysis , increase plasma FFA concentration increase fatty acid supply liver . Thus , fatty acid oxidation ketogenesis enhance . Our recent work show liraglutide , GLP 1 agonist , improve glycemic control reduce glycemic excursion patient type 1 diabetes within day initiation treatment . With background , investigator hypothesize suppression glucagon liraglutide patient type 1 diabetes may protect lipolysis , increase bio-availability FFAs , ketogenesis ketoacidosis . On hand , addition SGLT 2 inhibitor shift biochemical change direction thus increase ketogenesis /ketoacidosis . It essential investigate area prior study investigate acute effect liraglutide/Dapagliflozin FFAs ketogenesis . This study first randomize control prospective study investigate effect liraglutide/dapagliflozin ketogenesis . Also , would important measure mediator inflammation time investigate whether concomitant change inflammatory factor parallel lipolysis ketogenesis . After screen visit , subject meet inclusion exclusion criterion randomize receive single dose either liraglutide , dapagliflozin placebo monitor total 8 hour . The patient ( described 8.3 , cross study ) , get 2 treatment random order follow 2 visit ( one week apart ) total participation 2 weeks+1 day .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>1 . Type 1 Diabetes continuous subcutaneous insulin infusion ( CSII , also know insulin pump ) . 2 . Undetectable c peptide ( cpeptide &lt; 0.1 ng/ml ) . 3 . HbA1c le equal 8.5 % . 4 . Age 1875 inclusive 1 . Type 1 diabetes less 12 month 2 . Coronary event/ procedure ( MI , Unstable angina , CABG , PCI ) last four week 3 . Hepatic disease ( Transaminase &gt; 3 time normal ) Cirrhosis 4 . Renal impairment ( serum eGFR &lt; 30ml/min/1.73m2 ) 5 . HIV Hepatitis B C positive status 6 . History pancreatitis , i.e. , history gallstone , alcohol abuse hypertriglyceridemia 7 . Pregnancy 8 . Inability give inform consent 9 . History Gastroparesis 10 . Personal Family History medullary thyroid carcinoma MEN 2 syndrome 11 . Alcoholism 12 . Hypertriglyceridemia ( &gt; 500 mg/dl ) . 13 . Those history bladder cancer , diabetic ketoacidosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetic ketoacidosis</keyword>
	<keyword>Insulin</keyword>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>glucose ( sugar ) control</keyword>
	<keyword>SGLT-2 inhibitor</keyword>
</DOC>